Impact on patients' treatment outcomes of XpertMTB/RIF implementation for the diagnosis of tuberculosis: Follow-up of a stepped-wedge randomized clinical trial

PLoS ONE

Volumn 10, Issue 4, 2015, Pages

  Trajman, Anete ^a,b   Durovni, Betina ^a,c   Saraceni, Valeria ^c,d   Menezes, Alexandre ^e   Cordeiro Santos, Marcelo ^d,f   Cobelens, Frank ^g,h   Van Den Hof, Susan ^g,h  

^a FEDERAL UNIVERSITY OF RIO DE JANEIRO   (Brazil)

^b MCGILL UNIVERSITY   (Canada)

^c Health Secretariat of Rio de Janeiro City   (Brazil)

^d Tropical Medicine Foundation Dr Heitor Vieira Dourado   (Brazil)

^e Global Health Strategies   (Brazil)

^f Amazonas State University   (Brazil)

^g AMSTERDAM INSTITUTE FOR GLOBAL HEALTH AND DEVELOPMENT   (Netherlands)

^h KNCV TUBERCULOSIS FOUNDATION   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

RIFAMPICIN; DIAGNOSTIC KIT;

ADOLESCENT; ADULT; ARTICLE; BRAZIL; CHILD; CLINICAL EFFECTIVENESS; CONTROLLED STUDY; EARLY DIAGNOSIS; FALSE POSITIVE RESULT; FEMALE; FOLLOW UP; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INCIDENCE; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; MOLECULAR DIAGNOSIS; MORTALITY; OUTCOME ASSESSMENT; PRESCHOOL CHILD; RANDOMIZED CONTROLLED TRIAL; SCHOOL CHILD; SPUTUM SMEAR; TUBERCULOSIS; TUBERCULOSIS RAPID TEST; YOUNG ADULT; AGED; ANTIBIOTIC RESISTANCE; DIAGNOSTIC KIT; DRUG EFFECTS; GENETICS; INFANT; ISOLATION AND PURIFICATION; MICROBIOLOGY; MYCOBACTERIUM TUBERCULOSIS; SPUTUM; TREATMENT OUTCOME; UTILIZATION;

ADOLESCENT; ADULT; AGED; CHILD; CHILD, PRESCHOOL; DRUG RESISTANCE, MICROBIAL; FEMALE; FOLLOW-UP STUDIES; HUMANS; INFANT; MALE; MIDDLE AGED; MYCOBACTERIUM TUBERCULOSIS; REAGENT KITS, DIAGNOSTIC; RIFAMPIN; SPUTUM; TREATMENT OUTCOME; TUBERCULOSIS;

EID: 84928678299     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0123252     Document Type: Article

References (15)

1. Boehme CC, Nabeta P, Hillemann D, Nicol MP, Shenai S, Krapp F, et al. Rapid molecular detection of tuberculosis and rifampin resistance. N Engl J Med. 2010; 363: 1005-1015. doi: 10.1056/NEJMoa0907847 PMID: 20825313
2. Steingart KR, Sohn H, Schiller I, Kloda LA, Boehme CC, Pai M, et al. Xpert MTB/RIF assay for pulmonary tuberculosis and rifampicin resistance in adults. Cochrane Database Syst Rev. 2013; 1: CD009593. doi: 10.1002/14651858.CD009593.pub2 PMID: 23440842
3. Keeler E, Perkins MD, Small P, Hanson C, Reed S, Cunningham J, et al. Reducing the global burden of tuberculosis: the contribution of improved diagnostics. Nature. 2006; 444: 49-57. PMID: 17159894
4. World Health Organization. Road map for rolling out Xpert MTB/RIF for rapid diagnosis of TB and MDR-TB [Internet]. WHO.; 2010. Available: http://www.who.int/tb/laboratory/roadmap-xpert-mtb-rif.pdf
5. Durovni B. XpertMTB/Rif for diagnosing pulmonary tuberculosis: a stepped-wedge cluster-randomized trial. PLoS Med (in press). 2014;
6. Theron G, Zijenah L, Chanda D, Clowes P, Rachow A, Lesosky M, et al. Feasibility, accuracy, and clinical effect of point-of-care Xpert MTB/RIF testing for tuberculosis in primary-care settings in Africa: a multicentre, randomised, controlled trial. Lancet. 2014; 383: 424-435. doi: 10.1016/S0140-6736(13) 62073-5 PMID: 24176144
7. Nakiyingi L, Bwanika JM, Kirenga B, Nakanjako D, Katabira C, Lubega G, et al. Clinical predictors and accuracy of empiric tuberculosis treatment among sputum smear-negative HIV-infected adult TB suspects in Uganda. PLoS ONE. 2013; 8: e74023. doi: 10.1371/journal.pone.0074023 PMID: 24040151
8. Churchyard G. Effect of Xpert MTB/RIF on early mortality in adults with suspected TB: a pragmatic randomized trial [Internet]. CROI; 2014; Boston, USA. Available: http://www.croiwebcasts.org/console/player/22178?mediaType = slideVideo&
9. Hayes RJ, Moulton LH. Cluster randomized trials. Boca Raton, Fla.; London: Chapman & Hall/CRC; 2009.
10. Camargo KR Jr, Coeli CM. [Reclink: an application for database linkage implementing the probabilistic record linkage method]. Cad Saude Publica. 2000; 16: 439-447. PMID: 10883042
11. World Health Organization, Stop TB Initiative (World Health Organization). The treatment of tuberculosis guidelines. [Internet]. Geneva: World Health Organization; 2010. Available: http://site.ebrary.com/id/10411821
12. Theron G, Peter J, Dowdy D, Langley I, Squire SB, Dheda K. Do high rates of empirical treatment undermine the potential effect of new diagnostic tests for tuberculosis in high-burden settings? The Lancet Infectious Diseases. 2014; doi: 10.1016/S1473-3099(13)70360-8
13. Tiemersma EW, van der Werf MJ, Borgdorff MW, Williams BG, Nagelkerke NJD. Natural history of tuberculosis: duration and fatality of untreated pulmonary tuberculosis in HIV negative patients: a systematic review. PLoS ONE. 2011; 6: e17601. doi: 10.1371/journal.pone.0017601 PMID: 21483732
14. Lawn SD, Wood R, De Cock KM, Kranzer K, Lewis JJ, Churchyard GJ. Antiretrovirals and isoniazid preventive therapy in the prevention of HIV-associated tuberculosis in settings with limited health-care resources. Lancet Infect Dis. 2010; 10: 489-498. doi: 10.1016/S1473-3099(10)70078-5 PMID: 20610331
15. Osman M, Simpson JA, Caldwell J, Bosman M, Nicol MP. GeneXpert MTB/RIF Version G4 for Identification of Rifampin-Resistant Tuberculosis in a Programmatic Setting. J Clin Microbiol. 2014; 52: 635-637. doi: 10.1128/JCM.02517-13 PMID: 24478501